Correlation of TP53 and MDM2 genotypes with response to therapy in sarcoma
The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Relatively few sarcomas harbor TP53 (tumor protein p53) mutations, but in many cases, amplification of MDM2 (murine double minute 2) effectively inactivate p53. The p53 pathway activity can also be affected by normal genetic variation. METHODS: The mutation status of TP53 and expression of MDM2, TP53, and their genetic variants SNP309 and R72P (Arg72Pro) were investigated in 125 sarcoma patient samples and 18 sarcoma cell lines. Association of the different genotypes and gene aberrations with chemotherapy response and survival, as well as response to MDM2 antagonists in vitro was evaluated. RESULTS: Twenty‐two percent of the tumors had mutant TP53 and 20% MDM2 gene amplification. Patients with wild‐type TP53 (TP53Wt) tumors had improved survival (P < .001) and TP53Wt was an independent prognostic factor (hazard ratio = 0.41; 95% confidence interval = 0.23‐0.74; P = .03). Interestingly, there was a trend toward longer time to progression after chemotherapy for tumors with the apoptosis‐prone p53 variant R72 (P = .07), which was strongest with doxorubicin/ifosfamide‐based regimens (P = .01). Liposarcomas had low R72 frequency (33% versus 56%), but increased levels of MDM2 and MDM4 (51% and 11%, P < .001). MDM2 overexpression on a TP53Wt background predicted better response to MDM2 antagonist Nutlin‐3a, irrespective of R72P or SNP309 status. CONCLUSIONS: Improved survival after chemotherapy was found in patients with TP53Wt tumors harboring the R72 variant. MDM2 overexpression in TP53Wt tumors predicted good response to MDM2 antagonists, irrespective of R72P or SNP309 status. Thus, detailed TP53 and MDM2 genotype analyses prior to systemic therapy are recommended. Cancer 2013. © 2012 American Cancer Society.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Amplification of a gene encoding a p53-associated protein in human sarcomas
Oliner, J. D., Kinzler, K. W., Meltzer, P. S., George, D. L., & Vogelstein, B. (1992) · Nature · doi:10.1038/358080a0 · Cited by 1,949
Petitjean, A., Mathe, E., Kato, S., Ishioka, C., Tavtigian, S. V., Hainaut, P., & Olivier, M. (2007) · Human Mutation · doi:10.1002/humu.20495 · Cited by 1,598 · cited 1×
“Median age at diagnosis (range), y 58 (8-87)”
BackgroundBond, G. L., Hu, W., Bond, E. E., Robins, H., Lutzker, S. G., Arva, N. C., Bargonetti, J., Bartel, F., Taubert, H., Wuerl, P., et al. (2004) · Cell · doi:10.1016/j.cell.2004.11.022 · Cited by 1,265 · cited 1×
“Median age at diagnosis (range), y 58 (8-87)”
BackgroundSmall-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy
Tovar, C., Rosinski, J., Filipovic, Z., Higgins, B., Kolinsky, K., Hilton, H., Zhao, X., Vu, B. T., Qing, W., Packman, K., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0507493103 · Cited by 708
Self-citationMDMX overexpression prevents p53 activation by the MDM2 inhibitor Nutlin
Hu, B., Gilkes, D. M., Farooqi, B., Sebti, S. M., & Chen, J. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.c600147200 · Cited by 236
Ito, M., Barys, L., O'Reilly, T., Young, S., Gorbatcheva, B., Monahan, J., Zumstein-Mecker, S., Choong, P. F., Dickinson, I., Crowe, P., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2050 · Cited by 115
Research works printed but not linked: 37
- 10.1016/j.cellbi.2006.11.012 · DOI · Paper page
- Andreassen A, 1993, p53 abnormalities in different subtypes of human sarcomas, Cancer Res., 53, 468
- 10.1007/s000180050273 · DOI · Paper page
- 10.1093/jnci/86.17.1297 · DOI · Paper page
- 10.1093/nar/26.15.3453 · DOI · Paper page
- 10.1038/sj.onc.1206671 · DOI
- Li FP, 1988, A cancer family syndrome in twenty‐four kindreds, Cancer Res., 48, 5358
- 10.1038/nrc2584 · DOI · Paper page
- 10.1002/ijc.23454 · DOI
- 10.1158/0008-5472.CAN-05-0825 · DOI · Paper page
- 10.1158/1055-9965.EPI-07-0634 · DOI
- 10.1159/000154228 · DOI · Paper page
- 10.1038/ng1093 · DOI · Paper page
- 10.1128/MCB.19.2.1092 · DOI · Paper page
- 10.1038/sj.onc.1207428 · DOI · Paper page
- 10.1038/sj.onc.1210199 · DOI · Paper page
- 10.1182/blood-2008-05-158634 · DOI
- 10.1002/ijc.23541 · DOI
- 10.1016/j.ccr.2010.12.019 · DOI
- Fletcher CDM, 2002, World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Soft Tissue and Bone
- 10.1002/gcc.20717 · DOI · Paper page
- 10.1002/ijc.22643 · DOI · Paper page
- 10.1186/1471-2407-11-211 · DOI · Paper page
- 10.1073/pnas.96.13.7382 · DOI · Paper page
- Onat OE, 2006, MDM2 T309G polymorphism is associated with bladder cancer, Anticancer Res., 26, 3473
- Toguchida J, 1992, Mutation spectrum of the p53 gene in bone and soft tissue sarcomas, Cancer Res., 52, 6194
- 10.1002/ijc.23380 · DOI · Paper page
- 10.1002/(SICI)1098-2264(199612)17:4<254::AID-GCC7>3.0.CO;2-2 · doi:10.1002/(sici)1098-2264(199612)17:4<254::aid-gcc7>3.0.co;2-2
- 10.1038/sj.onc.1201135 · DOI
- 10.1002/(SICI)1098-2264(199901)24:1<30::AID-GCC5>3.0.CO;2-P · DOI · Paper page
- 10.1016/j.cancergencyto.2004.08.005 · DOI · Paper page
- 10.1158/1078-0432.CCR-08-2249 · DOI
- 10.1097/CCO.0b013e3283412dfa · DOI · Paper page
- 10.1158/1541-7786.1.2.1 · DOI · Paper page
- 10.1002/1097-0215(20010520)95:3<168::AID-IJC1029>3.0.CO;2-A · DOI · Paper page
- 10.1038/75586 · DOI · Paper page
- 10.4161/cc.9.7.11255 · DOI · Paper page
Cited by
Drugging the p53 pathway: understanding the route to clinical efficacy
Khoo, K. H., Verma, C. S., & Lane, D. P. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4236 · Cited by 719
The Roles of MDM2 and MDMX in Cancer
Karni-Schmidt, O., Lokshin, M., & Prives, C. (2016) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-012414-040349 · Cited by 296
Verreault, M., Schmitt, C., Goldwirt, L., Pelton, K., Haidar, S., Levasseur, C., Guehennec, J., Knoff, D., Labussière, M., Marie, Y., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1015 · Cited by 114
Deben, C., Wouters, A., de Beeck, K. O., van Den Bossche, J., Jacobs, J., Zwaenepoel, K., Peeters, M., Van Meerbeeck, J., Lardon, F., Rolfo, C., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.4433 · Cited by 73
“well-differentiated and dedifferentiated liposarcomas, because MDM2 gene amplification occurs in about 20% of all cases, making them adequate study subjects [6, 28, 31].”
BackgroundCDK4 inhibition diminishes p53 activation by MDM2 antagonists
Sriraman, A., Dickmanns, A., Najafova, Z., Johnsen, S. A., & Dobbelstein, M. (2018) · Cell Death & Disease · doi:10.1038/s41419-018-0968-0 · Cited by 40
Metadata
- Authors
- Ohnstad, H. O., Castro, R., Sun, J., Heintz, K., Vassilev, L. T., Bjerkehagen, B., Kresse, S. H., Meza‐Zepeda, L. A., & Myklebost, O.
- Venue
- Cancer
- Publisher
- Wiley
- Published
- 2012-11-16
- Volume
- 119
- Issue
- 5
- Pages
- 1013-1022
- ISSN
- 0008-543X (ISSN-L)
- 1097-0142
- OpenAlex
- W2071028149
- Cited by
- 42
- References
- 6
- FWCI
- 2.56
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Correlation of TP53 and MDM2 genotypes with response to therapy in sarcoma. https://app.cochat.ai/papers/10.1002/cncr.27837
- The paper
- Ohnstad, H. O., Castro, R., Sun, J., Heintz, K., Vassilev, L. T., Bjerkehagen, B., Kresse, S. H., Meza‐Zepeda, L. A., & Myklebost, O. (2013). Correlation of TP53 and MDM2 genotypes with response to therapy in sarcoma. Cancer. https://doi.org/10.1002/cncr.27837
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.